Creative Medical Technology Stock (NASDAQ:CELZ)

Revenue Ownership Financials Chart

Previous Close

$3.15

52W Range

$1.96 - $10.28

50D Avg

$2.41

200D Avg

$3.46

Market Cap

$5.61M

Avg Vol (3M)

$39.93K

Beta

5.03

Div Yield

CELZ Company Profile

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 06, 2015

Website

CELZ Performance

CELZ Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$9.00K	$88.60K	$87.75K
Operating Income	$-5.53M	$-10.24M	$-3.13M
Net Income	$-5.29M	$-10.04M	$14.93M
EBITDA	$-5.53M	$-10.05M	$-3.03M
Basic EPS	$-3.76	$-9.21	$45.97
Diluted EPS	$-3.76	$-9.19	$45.97

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
ICU	SeaStar Medical Holding Corporation
ADXN	Addex Therapeutics Ltd
SNGX	Soligenix, Inc.
ZVSA	ZyVersa Therapeutics, Inc.
VRAX	Virax Biolabs Group Limited
REVB	Revelation Biosciences, Inc.
QNRX	Quoin Pharmaceuticals, Ltd.
SONN	Sonnet BioTherapeutics Holdings, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.
ATXI	Avenue Therapeutics, Inc.
UNCY	Unicycive Therapeutics, Inc.
PALI	Palisade Bio, Inc.